SUMMIT THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.65 USD | -2.72% |
|
+5.92% | +78.16% |
| May. 07 | Citigroup Starts Summit Therapeutics With Buy Rating, $7 Price Target | MT |
| May. 01 | Transcript : Summit Therapeutics Inc., Q1 2024 Earnings Call, May 01, 2024 |
Evolution of the average Target Price on Summit Therapeutics Inc.
Price target over the last 5 years
History of analyst recommendation changes
14c50b5.hiUA7tpOmYW8A0k6xHJDTDoKoRSHroietkSBkIhjLbc.ynp6lqM-9cjEXDNVgEMwBktk6F_W9sqp7yrmos0Pa_q3EVq6jAr06ZFrEA~c91aebd13ce839ba3ceca55b4c14be5a
More recommendations
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.716
GBP
Average target price
5.994
GBP
Spread / Average Target
+61.30%
High Price Target
6.406
GBP
Spread / Highest target
+72.40%
Low Price Target
5.581
GBP
Spread / Lowest Target
+50.20%
Consensus detail
Consensus revision (last 18 months)
Analysts covering Summit Therapeutics Inc.
| Citigroup | |
| Stifel Nicolaus |
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- SMMT Stock
- Consensus Summit Therapeutics Inc.
